Comparison 3. SENSITIVITY ANALYSIS: RISPERIDONE vs PLACEBO (based on attrition).
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Mental state: 1. no clinically significant response (defined by PANSS/BPRS) ‐ short term (up to 12 weeks) | 6 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
1.1 defined by PANSS/BPRS <20% decline | 6 | 864 | Risk Ratio (M‐H, Random, 95% CI) | 0.64 [0.52, 0.78] |
1.2 defined by PANSS/BPRS <20% decline (without studies with >50% left the study early) | 3 | 589 | Risk Ratio (M‐H, Random, 95% CI) | 0.77 [0.67, 0.88] |